The different time-dependent performance of multiparametric molecular signatures indicates that molecular features of ER+ breast cancers may be identified to improve prediction of residual risk in order to spare those patients with significantly low risk of late recurrence from extended endocrine therapy. This evidence concerns the gene ESR1 and breast carcinoma.